Your session is about to expire
← Back to Search
Gusacitinib for Lupus
Study Summary
"This trial is testing a new drug called Gusacitinib in people with lupus, a disease where the immune system attacks healthy tissue. The study will involve participants aged 18 and older and will
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are new participants currently being accepted for enrollment in this clinical trial?
"As per clinicaltrials.gov, this investigation is not presently open for participant enrollment. Originally shared on 2/7/2024 and last modified on 2/1/2024, the trial's recruitment phase has ceased. Nonetheless, there are currently 146 alternative studies actively seeking participants."
What are the safety implications of Gusacitinib for individuals receiving treatment?
"Our team at Power rated the safety of Gusacitinib a 1 on our scale, as this Phase 1 trial has minimal data supporting both its safety and effectiveness."
Is the clinical trial open to individuals above the age of 85?
"To be considered for this research study, individuals aged between 18 and 99 are eligible. It is noteworthy that there are separate trials available specifically designed for those under 18 years old (26 trials) and over 65 years old (124 trials)."
Am I eligible to enroll in this clinical trial?
"Individuals diagnosed with lupus aged between 18 and 99 are eligible to participate in this study, which aims to enroll a total of 60 participants."
Share this study with friends
Copy Link
Messenger